The Post Roll: Value Case for Trulieve (TRUL) & Toxic Pot Stocks


Scott Willis and Thomas George take stock of the battered down cannabis sector, even though sales have picked up during the coronavirus crisis the stocks have continued to trade like trash.

The Value Case for Trulieve

With so much carnage in the sector we thought it would make sense to look if there is a “value investing” case emerging for any specific stocks.  We compared one of the best run companies in the sector – Trulieve (CSE: TRUL) vs. alcohol peers.

It’s getting very interesting to say the least.


Pot Stocks: Have the Con Artists Left the Building?

The cannabis sector has been notorious for creating bag holders, founders not creating any sustaining value and selling shares across the board.   The chart below illustrates the carnage, Aurora (NYSE: ACB) and Tilray (NYSE: TLRY) down nearly 90% in a year – no real stocks ever shed this much value.

Scott examines the sector to see whether the impostors have left the sector completely.  This sector won’t work till all the corporate governance garbage is taken to the curb.


Does Canopy have a Game Changer with Drinks?

Scott weighs in about Canopy Growth’s (NYSE: CGC) fast onset cannabis drink, this has the potential to be a real game changer for the industry… but is it enough to move the dial to make Canopy a bargain?  We don’t think so, the valuation is simply too stretched and too much growth is already baked into the stock.

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post


Fire and Flower Announces A $25 Million Cash Raise, Are Investors Done Being Diluted?

Back on December 17th, we wrote an article questioning Fire and Flowers’ ability to pay off upcoming debt maturities. At the time the company had $43 million of cash against


Curaleaf Q1 Shows Company May Have to Test Market’s Tolerance for More Borrowing

UPDATE: After the release of full quarterly financials, we are much more bullish on the company than we were in the above video. Multi-State cannabis operator Curaleaf (CNSX: CURA) reported


Pot Stocks Post Roll: Weed Beta (VLNS), Growers vs. Suppliers (GRWG), MedMen (MMEN)

In this week’s edition of the Post Roll Thomas George and Scott Willis survey the coronavirus market carnage! They examine the market beta of cannabis stocks and Valens (TSXV: VLNS)

Share via
Copy link
Powered by Social Snap